Epizyme (NASDAQ:EPZM) Stock Rating Lowered by BidaskClub

BidaskClub downgraded shares of Epizyme (NASDAQ:EPZM) from a sell rating to a strong sell rating in a report issued on Thursday, December 21st.

A number of other equities research analysts have also recently commented on the stock. Cann reaffirmed a buy rating and issued a $26.00 price target on shares of Epizyme in a report on Tuesday, December 12th. Royal Bank of Canada cut shares of Epizyme from an outperform rating to a sector perform rating and lowered their price target for the stock from $20.00 to $16.00 in a report on Thursday, November 2nd. HC Wainwright reaffirmed a buy rating and issued a $25.00 price target on shares of Epizyme in a report on Thursday, November 2nd. ValuEngine cut shares of Epizyme from a hold rating to a sell rating in a report on Monday, November 6th. Finally, Oppenheimer set a $26.00 price target on shares of Epizyme and gave the stock a buy rating in a report on Tuesday, December 12th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company’s stock. Epizyme currently has an average rating of Buy and a consensus price target of $22.40.

Shares of Epizyme (NASDAQ:EPZM) opened at $14.85 on Thursday. Epizyme has a 1-year low of $9.30 and a 1-year high of $20.45.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.02. analysts anticipate that Epizyme will post -2.23 earnings per share for the current fiscal year.

In other Epizyme news, insider Peter Tai-Ching Ho sold 15,000 shares of the business’s stock in a transaction on Tuesday, October 24th. The shares were sold at an average price of $16.44, for a total transaction of $246,600.00. Following the sale, the insider now owns 23,123 shares of the company’s stock, valued at approximately $380,142.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 25.20% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP raised its holdings in Epizyme by 61.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 65,194 shares of the biopharmaceutical company’s stock valued at $1,118,000 after acquiring an additional 24,807 shares during the period. NEA Management Company LLC grew its position in shares of Epizyme by 3.2% during the 3rd quarter. NEA Management Company LLC now owns 6,460,851 shares of the biopharmaceutical company’s stock valued at $123,079,000 after purchasing an additional 200,000 shares in the last quarter. State Street Corp grew its position in shares of Epizyme by 59.6% during the 2nd quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock valued at $26,644,000 after purchasing an additional 658,727 shares in the last quarter. Federated Investors Inc. PA grew its position in shares of Epizyme by 477.6% during the 2nd quarter. Federated Investors Inc. PA now owns 89,505 shares of the biopharmaceutical company’s stock valued at $1,352,000 after purchasing an additional 74,009 shares in the last quarter. Finally, University of Notre Dame DU Lac grew its position in shares of Epizyme by 25.0% during the 3rd quarter. University of Notre Dame DU Lac now owns 191,719 shares of the biopharmaceutical company’s stock valued at $3,652,000 after purchasing an additional 38,368 shares in the last quarter. 85.28% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.thelincolnianonline.com/2018/01/14/epizyme-epzm-lowered-to-strong-sell-at-bidaskclub-updated-updated.html.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply